What technical signals does Jeonjinbio (110020) have?

Jeonjinbio current technical signals: no active technical signal.

Is Jeonjinbio a cup-and-handle pattern?

No. Jeonjinbio has no valid cup-and-handle signal right now.

What are Jeonjinbio's financials and valuation?

Jeonjinbio's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Jeonjinbio

110020 · KOSDAQ

₩1,973+1.70%

2026-09-04 close

Jeonjinbio last closed at ₩1,973 (+1.70%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

303 picks

Next-day win rate

50.7%

Avg next-day

-0.11%

vs market

-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Overall: 필수소비재 74/98 · top 75%

Factor composite · relative position in sector

PER 4.11 · PBR 1.01 — own-history percentile 100/100 · 100/100

Open self-history band

PER100/100

PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024

Safe zoneFinancial-metric reference signal

Altman Z'' zoneZ'' 14.18

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': 14.18
Beneish M-Score: -1.89
Sloan accrual: 7.11%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +22.9% 성장하면서 영업이익률이 -11.5%에서 4.8%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +22.9%영업이익률 -11.5%→4.8%FCF 3,400

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

Positive ROAPass
Positive OCFPass
Improving ΔROAPass
Accruals (OCF > net income)Not passed

Leverage & liquidity

Lower debtPass
Higher current ratioPass
No new sharesPass

Efficiency

Higher gross marginPass
Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 872% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

필수소비재

This stock is in 필수소비재: revenue rank 94 of 97, share 0%.

94 / 970%revenue share

Who dominates this industry?

1CJ제일제당20.4%
2하림지주8.5%
3동원산업6.2%
4KT&G4.1%
5대상홀딩스3.7%
6전진바이오팜0%

Concentration

DistributedCR3 35.1%

HHI 65397 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

MixedConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p: 5.94
Direction: 확대
Level: 좁음
Years: 6

Value lens

P90/P10: 5.1
Median P/B: 0.67
Level: 보통
n: 92

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin: 4.8%
Interest coverage: 2.1x
Return on equity (ROE): 24.6%

Operating margin −5pp

Operating loss

Interest coverageBase 2.1x-0.1x

Return on equity (ROE)Base 24.6%-2.7%

Revenue −15%

Tolerable

Interest coverageBase 2.1x1.8x

Return on equity (ROE)Base 24.6%2%

Interest rate +2pp

Tolerable

Interest coverageBase 2.1x2x

Return on equity (ROE)Base 24.6%2.6%

Interest coverage limit

Current margin 2.5pp

Interest coverage limit at an operating margin of 2.2%

Interest expense coverage threshold

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

이태훈9.75%2026-08-21 · 증감 +0.82%p

Connections

AI-extracted related companies · for reference

Suppliers

롯데케미칼Price comovement r=0.12 (1 year)LG화학Price comovement r=0.14 (1 year)

Customers

아모레퍼시픽Price comovement r=0.05 (1 year)LG생활건강Price comovement r=0.15 (1 year)애경산업Price comovement r=0.14 (1 year)유한양행Price comovement r=0.12 (1 year)코스맥스Price comovement r=0.04 (1 year)한국콜마Price comovement r=0.04 (1 year)

Competitors

바이오니아Price comovement r=0.09 (1 year)

Same theme

대상Price comovement r=0.20 (1 year)CJ제일제당Price comovement r=0.17 (1 year)에이프로젠Price comovement r=0.16 (1 year)삼성바이오로직스Price comovement r=0.15 (1 year)

🔗 See in the full market map →

Recent filings

Jeonjinbio's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Jeonjinbio

What technical signals does Jeonjinbio (110020) have?: Jeonjinbio current technical signals: no active technical signal.
Is Jeonjinbio a cup-and-handle pattern?: No. Jeonjinbio has no valid cup-and-handle signal right now.
What are Jeonjinbio's financials and valuation?: Jeonjinbio's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy